Home » Stocks » ACAD

ACADIA Pharmaceuticals Inc. (ACAD)

Stock Price: $48.69 USD -1.05 (-2.11%)
Updated Feb 24, 2021 4:00 PM EST - Market closed
After-hours: $47.75 -0.94 (-1.93%) Feb 24, 7:58 PM
Market Cap 7.77B
Revenue (ttm) 419.07M
Net Income (ttm) -267.86M
Shares Out 158.13M
EPS (ttm) -1.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 24
Last Price $48.69
Previous Close $49.74
Change ($) -1.05
Change (%) -2.11%
Day's Open 49.77
Day's Range 48.33 - 50.40
Day's Volume 1,018,358
52-Week Range 30.02 - 58.72

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 10 hours ago

Acadia (ACAD) delivered earnings and revenue surprises of 12.50% and -1.52%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 12 hours ago

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced financial results for the fourth quarter and full year ended December 31, 2020. “Acadia delivered strong ...

Benzinga - 1 day ago

On Wednesday, February 24, ACADIA Pharmaceuticals (NASDAQ:ACAD) will release its latest earnings report. Check out Benzinga's preview to understand the implications.

Business Wire - 5 days ago

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the launch of MoreThanMemoryLoss.com, a new website with educational resources designed to help caregiver...

Business Wire - 6 days ago

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following investor conferences: 10th Annual SVB Leerink Global Healthcare...

Zacks Investment Research - 1 week ago

Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 2 weeks ago

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2020 financial results on Wednesday, February 24, 2021, ...

Seeking Alpha - 3 weeks ago

After a nice close to 2020, Acadia's shares hit a slick spot in 2021.When they are waxing, as they so often do, Acadia's shares are good candidates for selling covered calls.

Business Wire - 4 weeks ago

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Michael Yang, Executive Vice President and Chief Commercial Officer, will be leaving the organizatio...

Seeking Alpha - 1 month ago

ACADIA Pharmaceuticals Inc.'s (ACAD) CEO Stephen Davis at 39th Annual J.P. Morgan Healthcare Conference (Transcript)

Business Wire - 1 month ago

DENVER--(BUSINESS WIRE)--Shuman, Glenn & Stecker Investigates Acadia Pharmaceuticals, Inc.

Business Wire - 2 months ago

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021, a...

24/7 Wall Street - 2 months ago

After an incredibly wild and wooly year for investors, many across Wall Street are cautiously optimistic for 2021.

Other stocks mentioned: NBIX, QURE, VRTX, ZGNX
Zacks Investment Research - 2 months ago

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?

24/7 Wall Street - 2 months ago

The health care sector as a whole has been a top performer this year, and there is every reason to believe that strong performance will carry through to 2021.

Other stocks mentioned: CVS, HR, QURE
Zacks Investment Research - 2 months ago

Let's see if Acadia Healthcare (ACHC) stock is a good choice for value-oriented investors right now from multiple angles.

Other stocks mentioned: ACHC
Seeking Alpha - 3 months ago

ACADIA Pharmaceuticals Inc.'s (ACAD) Management Presents at 2020 Stifel Virtual Healthcare Conference (Transcript)

Business Wire - 3 months ago

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17, 2020, at 3...

Zacks Investment Research - 3 months ago

ACADIA's (ACAD) earnings fall shy of estimates in the third quarter while revenues beat the same. The company maintains its net sales guidance for Nuplazid.

The Motley Fool - 3 months ago

The good news? Sales of Nuplazid are soaring.

Seeking Alpha - 3 months ago

ACADIA Pharmaceuticals Inc.'s (ACAD) CEO Steve Davis on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Acadia (ACAD) delivered earnings and revenue surprises of -42.11% and 1.52%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 3 months ago

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet me...

Zacks Investment Research - 3 months ago

Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.

Other stocks mentioned: ALNY, AVRO, BHVN, BNTX
The Motley Fool - 3 months ago

The company's latest quarterly update impressed investors.

Other stocks mentioned: ACHC
Zacks Investment Research - 3 months ago

Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Insider Monkey - 3 months ago

Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another...

Business Wire - 3 months ago

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that scientific presentations highlighting new analyses of pimavanserin clinical study data in dementia-r...

Business Wire - 4 months ago

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter financial results on Wednesday, November 4, 2020, after the close of th...

Forbes - 4 months ago

Our indicative theme of Out Of Favor Healthcare Stocks is down by about -10% year-to-date, versus the S&P 500 which is up by about 8% year-to-date. This theme includes healthcare and pharma co...

Other stocks mentioned: ALKS, NBIX, ARWR, BMRN, IONS
Business Wire - 4 months ago

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Elizabeth (Betsy) Garofalo, M.D. to its Board of Directors. Dr. Garofalo is a biopharm...

Seeking Alpha - 5 months ago

ACADIA Pharmaceuticals, Inc. (ACAD) CEO Steve Davis Presents at Cantor Virtual Global Healthcare Conference (Transcript)

Seeking Alpha - 5 months ago

ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis Presents at Morgan Stanley 18th Annual Global Healthcare Conference (Transcript)

Other stocks mentioned: MS
PRNewsWire - 5 months ago

SAN DIEGO, Sept. 5, 2020 /PRNewswire/ -- Johnson Fistel, LLP is investigating potential claims on behalf of ACADIA Pharmaceuticals Inc.

Zacks Investment Research - 5 months ago

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?

InvestorPlace - 5 months ago

Spot the best cheap stocks to buy under $5 with the right catalyst at the right time, and it could lead to your next double-digit opportunity. The post 3 Cheap Stocks to Buy for Under $5 Now ...

Other stocks mentioned: APPS, BGFV
Business Wire - 5 months ago

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming virtual investor conferences: Citi 15th Annual BioPhar...

Business Wire - 5 months ago

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Dr.

Zacks Investment Research - 5 months ago

ACADIA (ACAD) purchases CerSci Therapeutics and in turn, secures the global rights to a suite of novel compounds for neurological disorders comprising non-opioid therapies for acute and chroni...

Business Wire - 5 months ago

SAN DIEGO & FORT WORTH, Texas--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the acquisition of CerSci Therapeutics, a clinical-stage biotechnology company with w...

Business Wire - 6 months ago

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at The JMP Securities CNS Forum on Wednesday, August 19, 2020, at 11:00 a.m.

Zacks Investment Research - 6 months ago

ACADIA (ACAD) beats on earnings and revenues for the second quarter. The company lifts the lower end of its net sales view for Nuplazid, driving the stock in pre-market trading.

Seeking Alpha - 6 months ago

ACADIA Pharmaceuticals, Inc. (ACAD) CEO Stephen Davis on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Acadia (ACAD) delivered earnings and revenue surprises of 38.64% and 4.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 6 months ago

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet me...

Newsfile Corp - 6 months ago

San Diego, California--(Newsfile Corp. - July 31, 2020) - If you would like to discuss your legal rights email leo@barrlaw.com or call (619) 780-3993.

Business Wire - 6 months ago

SANTA MARIA, Calif. & SAN DIEGO--(BUSINESS WIRE)---- $ACAD--Stephens & Stephens LLP is investigating the officers and directors of ACADIA Pharmaceuticals Inc.

Zacks Investment Research - 6 months ago

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 6 months ago

WASHINGTON & ATLANTA & SAN DIEGO--(BUSINESS WIRE)--UsAgainstAlzheimer’s, the Lewy Body Dementia Association and ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the results of a qual...

Zacks Investment Research - 6 months ago

ACADIA's (ACAD) second-quarter 2020 results are likely to reflect lower revenues from Nuplazid due to the adverse impacts of COVID-19.

About ACAD

ACADIA Pharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment f... [Read more...]

Industry
Biotechnology
IPO Date
May 27, 2004
CEO
Stephen Davis
Employees
580
Stock Exchange
NASDAQ
Ticker Symbol
ACAD
Full Company Profile

Financial Performance

In 2019, ACAD's revenue was $339.08 million, an increase of 51.50% compared to the previous year's $223.81 million. Losses were -$235.26 million, -4.05% less than in 2018.

Financial Statements

Analyst Forecasts

According to 20 analysts, the average rating for ACAD stock is "Buy." The 12-month stock price forecast is 62.25, which is an increase of 27.85% from the latest price.

Price Target
$62.25
(27.85% upside)
Analyst Consensus: Buy